Skincare Product Resulted from Fundamental Parthenogenic Stem Cell
Research
International Stem Cell Corporation (OTCBB:ISCO)
(www.intlstemcell.com),
has received excellent preliminary results for a new retail skin
rejuvenation product that has been developed as a result of its
fundamental research into Parthenogenic Stem Cells.
Scientists and clinicians at ISCO have discovered that a proprietary
combination of the special growth media for human skin tissue created by
the company, coupled with the by-products of the production of
Parthenogenic Stem Cells, appears to have a dramatic impact on the
restoration and retention of skin moisture. The product may have longer
term benefits for skin rejuvenation.
This discovery represents yet another example of the dynamic
relationship between the laboratory research products produced by ISCO's
wholly owned subsidiary, Lifeline Cell Technology and the fundamental
science of ISCO's stem cell research.
Further testing will be conducted to confirm this preliminary data. If
subsequent research supports the promising initial results, the Company
plans to launch, either directly or through a strategic partnership, a
new line of skin rejuvenation products based on this discovery.
Dr. Gregory S. Keller, a noted facial plastic surgeon, commented, "This
product shows early signs of being a significant breakthrough in
providing an oil free skin moisturizing product that might also provide
long term benefits in reducing wrinkles and other visible signs of the
natural aging process."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO 760-940-6383 kaldrich@intlstemcell.com or Jeffrey
Janus, President 760-940-6383 jjanus@intlstemcell.com or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |